Zhiying You
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 14 | 2023 | 486 | 1.490 |
Why?
| Polycystic Kidney, Autosomal Dominant | 9 | 2023 | 209 | 1.280 |
Why?
| Acute Kidney Injury | 7 | 2023 | 638 | 0.800 |
Why?
| Endothelium, Vascular | 6 | 2021 | 848 | 0.650 |
Why?
| Kidney Failure, Chronic | 6 | 2023 | 488 | 0.620 |
Why?
| Kidney | 10 | 2022 | 1184 | 0.560 |
Why?
| Vascular Stiffness | 4 | 2021 | 408 | 0.520 |
Why?
| Glomerular Filtration Rate | 11 | 2023 | 604 | 0.480 |
Why?
| Hypertension | 5 | 2021 | 1059 | 0.410 |
Why?
| Blood Pressure | 5 | 2021 | 1537 | 0.400 |
Why?
| Complement System Proteins | 4 | 2022 | 285 | 0.370 |
Why?
| Cardiovascular Diseases | 4 | 2023 | 1729 | 0.370 |
Why?
| Fibroblast Growth Factors | 3 | 2020 | 162 | 0.350 |
Why?
| Complement Factor B | 2 | 2023 | 100 | 0.350 |
Why?
| Brachial Artery | 3 | 2020 | 176 | 0.330 |
Why?
| Uric Acid | 2 | 2021 | 148 | 0.320 |
Why?
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 11 | 0.310 |
Why?
| Creatinine | 2 | 2020 | 424 | 0.300 |
Why?
| Sodium | 2 | 2019 | 182 | 0.300 |
Why?
| Double-Blind Method | 9 | 2023 | 1663 | 0.290 |
Why?
| Vasodilation | 3 | 2020 | 416 | 0.290 |
Why?
| Critical Illness | 3 | 2023 | 643 | 0.290 |
Why?
| Endothelial Cells | 3 | 2021 | 685 | 0.280 |
Why?
| Cognition | 4 | 2023 | 983 | 0.270 |
Why?
| Prospective Studies | 13 | 2023 | 6218 | 0.270 |
Why?
| Kidney Diseases | 2 | 2022 | 350 | 0.270 |
Why?
| Kidney Transplantation | 4 | 2019 | 542 | 0.260 |
Why?
| Renal Dialysis | 2 | 2019 | 369 | 0.240 |
Why?
| Middle Aged | 23 | 2022 | 26806 | 0.230 |
Why?
| Bicarbonates | 2 | 2023 | 41 | 0.230 |
Why?
| Male | 32 | 2023 | 55663 | 0.230 |
Why?
| Cognitive Dysfunction | 2 | 2018 | 273 | 0.220 |
Why?
| Aged | 19 | 2022 | 19122 | 0.220 |
Why?
| Pregnancy Complications | 2 | 2018 | 430 | 0.220 |
Why?
| Humans | 44 | 2023 | 114935 | 0.210 |
Why?
| Sodium Bicarbonate | 2 | 2023 | 40 | 0.210 |
Why?
| Female | 31 | 2023 | 59580 | 0.210 |
Why?
| Ferric Compounds | 1 | 2022 | 40 | 0.200 |
Why?
| Sucrose | 1 | 2022 | 91 | 0.200 |
Why?
| Complement Factor H | 1 | 2022 | 60 | 0.200 |
Why?
| Cardiovascular System | 1 | 2023 | 126 | 0.200 |
Why?
| Biomarkers | 9 | 2023 | 3418 | 0.200 |
Why?
| Complement Pathway, Classical | 1 | 2021 | 19 | 0.190 |
Why?
| Disease Progression | 7 | 2023 | 2392 | 0.190 |
Why?
| Nephrosis, Lipoid | 1 | 2021 | 10 | 0.190 |
Why?
| Curcumin | 1 | 2021 | 28 | 0.190 |
Why?
| Nephrotic Syndrome | 1 | 2021 | 24 | 0.190 |
Why?
| Breathing Exercises | 1 | 2021 | 18 | 0.190 |
Why?
| Inhalation | 1 | 2021 | 26 | 0.190 |
Why?
| Respiratory Muscles | 1 | 2021 | 28 | 0.190 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2021 | 29 | 0.190 |
Why?
| Carcinoma, Basal Cell | 1 | 2022 | 68 | 0.190 |
Why?
| Peritoneal Dialysis | 1 | 2022 | 83 | 0.190 |
Why?
| Adult | 19 | 2023 | 30608 | 0.190 |
Why?
| Cardiolipins | 1 | 2021 | 72 | 0.190 |
Why?
| Kidney Glomerulus | 1 | 2021 | 100 | 0.180 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 89 | 0.180 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 35 | 0.180 |
Why?
| Allopurinol | 2 | 2018 | 53 | 0.180 |
Why?
| Immunoglobulin M | 1 | 2021 | 251 | 0.170 |
Why?
| Bone Diseases | 1 | 2020 | 57 | 0.170 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 372 | 0.170 |
Why?
| Lipocalins | 1 | 2019 | 35 | 0.170 |
Why?
| Antigen-Antibody Complex | 1 | 2019 | 88 | 0.170 |
Why?
| Complement C3d | 1 | 2019 | 60 | 0.170 |
Why?
| Epitopes | 1 | 2021 | 436 | 0.170 |
Why?
| Spironolactone | 1 | 2019 | 28 | 0.160 |
Why?
| Vascular System Injuries | 1 | 2019 | 64 | 0.160 |
Why?
| Vascular Diseases | 1 | 2021 | 230 | 0.160 |
Why?
| Renal Replacement Therapy | 1 | 2019 | 66 | 0.160 |
Why?
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 38 | 0.160 |
Why?
| Isocitrate Dehydrogenase | 1 | 2018 | 38 | 0.160 |
Why?
| Accidental Falls | 1 | 2020 | 150 | 0.160 |
Why?
| Carotid Intima-Media Thickness | 1 | 2018 | 65 | 0.160 |
Why?
| Gene Amplification | 1 | 2018 | 97 | 0.160 |
Why?
| Complement Factor D | 1 | 2018 | 27 | 0.150 |
Why?
| Regional Blood Flow | 1 | 2020 | 424 | 0.150 |
Why?
| Fructose | 1 | 2018 | 100 | 0.150 |
Why?
| Infant Mortality | 1 | 2018 | 91 | 0.150 |
Why?
| Frailty | 1 | 2020 | 114 | 0.150 |
Why?
| Potassium, Dietary | 1 | 2018 | 10 | 0.150 |
Why?
| Propensity Score | 1 | 2019 | 224 | 0.150 |
Why?
| Infant, Low Birth Weight | 1 | 2018 | 125 | 0.150 |
Why?
| Metformin | 1 | 2021 | 278 | 0.150 |
Why?
| Complement Activation | 4 | 2022 | 340 | 0.150 |
Why?
| Hyponatremia | 1 | 2018 | 37 | 0.150 |
Why?
| Sodium, Dietary | 1 | 2018 | 36 | 0.150 |
Why?
| Antibodies | 1 | 2019 | 372 | 0.150 |
Why?
| Acidosis | 1 | 2018 | 87 | 0.150 |
Why?
| Cell-Derived Microparticles | 1 | 2018 | 58 | 0.150 |
Why?
| Blood Vessels | 1 | 2019 | 180 | 0.140 |
Why?
| Death | 1 | 2018 | 107 | 0.140 |
Why?
| Complement Pathway, Alternative | 1 | 2018 | 114 | 0.140 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2019 | 221 | 0.140 |
Why?
| Thrombocytopenia | 1 | 2019 | 177 | 0.140 |
Why?
| Cholecalciferol | 1 | 2017 | 47 | 0.140 |
Why?
| Calcitriol | 1 | 2017 | 53 | 0.140 |
Why?
| Vascular Calcification | 1 | 2018 | 107 | 0.140 |
Why?
| Pre-Eclampsia | 1 | 2018 | 165 | 0.140 |
Why?
| Hyperuricemia | 1 | 2016 | 44 | 0.140 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2018 | 182 | 0.140 |
Why?
| Living Donors | 1 | 2018 | 271 | 0.140 |
Why?
| Nitric Oxide | 1 | 2021 | 827 | 0.130 |
Why?
| Peripheral Arterial Disease | 1 | 2021 | 380 | 0.130 |
Why?
| Glioma | 1 | 2018 | 296 | 0.120 |
Why?
| Oxidative Stress | 1 | 2021 | 1084 | 0.120 |
Why?
| Skin Neoplasms | 1 | 2022 | 762 | 0.120 |
Why?
| Myocardial Infarction | 1 | 2022 | 929 | 0.120 |
Why?
| Recombinant Fusion Proteins | 1 | 2017 | 617 | 0.120 |
Why?
| Risk Factors | 7 | 2022 | 8637 | 0.110 |
Why?
| Longitudinal Studies | 5 | 2020 | 2382 | 0.110 |
Why?
| Dietary Supplements | 1 | 2017 | 458 | 0.110 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 752 | 0.110 |
Why?
| Interleukin-1 | 1 | 2017 | 966 | 0.110 |
Why?
| Case-Control Studies | 4 | 2021 | 3008 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2017 | 480 | 0.100 |
Why?
| Time Factors | 5 | 2021 | 6125 | 0.100 |
Why?
| Follow-Up Studies | 5 | 2019 | 4427 | 0.100 |
Why?
| Health Services Accessibility | 1 | 2017 | 765 | 0.100 |
Why?
| Young Adult | 6 | 2023 | 10478 | 0.090 |
Why?
| Pilot Projects | 3 | 2022 | 1372 | 0.090 |
Why?
| Pulse Wave Analysis | 2 | 2023 | 208 | 0.090 |
Why?
| Tooth Loss | 1 | 2011 | 31 | 0.090 |
Why?
| Liver | 1 | 2018 | 1634 | 0.090 |
Why?
| Brain Neoplasms | 1 | 2018 | 987 | 0.090 |
Why?
| Severity of Illness Index | 4 | 2020 | 2542 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2021 | 1215 | 0.090 |
Why?
| Vitamin D | 3 | 2018 | 341 | 0.090 |
Why?
| Risk Assessment | 4 | 2021 | 2975 | 0.090 |
Why?
| Prognosis | 3 | 2021 | 3344 | 0.080 |
Why?
| Mice | 5 | 2022 | 14935 | 0.080 |
Why?
| Cross-Sectional Studies | 4 | 2020 | 4407 | 0.080 |
Why?
| Nutritional Status | 2 | 2022 | 286 | 0.070 |
Why?
| Parathyroid Hormone | 2 | 2018 | 95 | 0.070 |
Why?
| Self Report | 1 | 2011 | 696 | 0.070 |
Why?
| Independent Living | 2 | 2018 | 84 | 0.070 |
Why?
| Brain | 1 | 2018 | 2372 | 0.070 |
Why?
| Child | 5 | 2023 | 18366 | 0.070 |
Why?
| Intensive Care Units | 2 | 2021 | 619 | 0.070 |
Why?
| Pregnancy Outcome | 2 | 2018 | 337 | 0.060 |
Why?
| Inflammation Mediators | 2 | 2019 | 476 | 0.060 |
Why?
| Obesity | 1 | 2017 | 2514 | 0.060 |
Why?
| Animals | 6 | 2022 | 31837 | 0.060 |
Why?
| United States | 5 | 2019 | 12211 | 0.060 |
Why?
| Pravastatin | 1 | 2023 | 28 | 0.060 |
Why?
| Incidence | 2 | 2021 | 2316 | 0.060 |
Why?
| Sex Factors | 2 | 2020 | 1721 | 0.060 |
Why?
| Plant Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| Cells, Cultured | 2 | 2021 | 3897 | 0.050 |
Why?
| Patched-1 Receptor | 1 | 2022 | 15 | 0.050 |
Why?
| Hyperphosphatemia | 1 | 2022 | 13 | 0.050 |
Why?
| Hypoalbuminemia | 1 | 2022 | 26 | 0.050 |
Why?
| Treatment Outcome | 3 | 2021 | 9105 | 0.050 |
Why?
| Nutrition Surveys | 1 | 2023 | 224 | 0.050 |
Why?
| Cohort Studies | 3 | 2018 | 4903 | 0.050 |
Why?
| Phosphorus | 1 | 2022 | 81 | 0.050 |
Why?
| Serum Albumin | 1 | 2022 | 134 | 0.050 |
Why?
| Drug Combinations | 1 | 2022 | 286 | 0.050 |
Why?
| Phosphates | 1 | 2022 | 158 | 0.050 |
Why?
| Gonadal Steroid Hormones | 1 | 2022 | 124 | 0.050 |
Why?
| Prevalence | 2 | 2018 | 2252 | 0.050 |
Why?
| Leukocyte Count | 1 | 2022 | 292 | 0.050 |
Why?
| Antibody Specificity | 1 | 2021 | 176 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 173 | 0.050 |
Why?
| Aged, 80 and over | 3 | 2018 | 6364 | 0.050 |
Why?
| Minerals | 1 | 2020 | 37 | 0.040 |
Why?
| Lymphocytes | 1 | 2022 | 333 | 0.040 |
Why?
| Mice, Inbred MRL lpr | 1 | 2019 | 37 | 0.040 |
Why?
| Colorado | 2 | 2021 | 4091 | 0.040 |
Why?
| Acute-Phase Proteins | 1 | 2019 | 64 | 0.040 |
Why?
| Lipocalin-2 | 1 | 2019 | 62 | 0.040 |
Why?
| Ultraviolet Rays | 1 | 2022 | 366 | 0.040 |
Why?
| Matched-Pair Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| Testosterone | 1 | 2022 | 343 | 0.040 |
Why?
| Allografts | 1 | 2019 | 122 | 0.040 |
Why?
| Monocytes | 1 | 2022 | 504 | 0.040 |
Why?
| Sex Characteristics | 1 | 2023 | 635 | 0.040 |
Why?
| Complement C4a | 1 | 2018 | 6 | 0.040 |
Why?
| Hepatocytes | 1 | 2019 | 196 | 0.040 |
Why?
| Half-Life | 1 | 2018 | 141 | 0.040 |
Why?
| Biological Availability | 1 | 2018 | 119 | 0.040 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 737 | 0.040 |
Why?
| Transplantation, Homologous | 1 | 2019 | 387 | 0.040 |
Why?
| Complement C5a | 1 | 2018 | 59 | 0.040 |
Why?
| Complement Membrane Attack Complex | 1 | 2018 | 33 | 0.040 |
Why?
| Clone Cells | 1 | 2018 | 248 | 0.040 |
Why?
| Chromosome Aberrations | 1 | 2018 | 138 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 250 | 0.040 |
Why?
| Area Under Curve | 1 | 2018 | 275 | 0.040 |
Why?
| Healthy Aging | 1 | 2018 | 17 | 0.040 |
Why?
| Fathers | 1 | 2018 | 45 | 0.040 |
Why?
| Ligands | 1 | 2019 | 565 | 0.040 |
Why?
| TRPP Cation Channels | 1 | 2018 | 63 | 0.040 |
Why?
| Rats, Wistar | 1 | 2018 | 368 | 0.040 |
Why?
| Infant, Newborn | 2 | 2018 | 5035 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 648 | 0.040 |
Why?
| Adolescent | 3 | 2021 | 17829 | 0.040 |
Why?
| Body Mass Index | 2 | 2017 | 1961 | 0.040 |
Why?
| ROC Curve | 1 | 2018 | 448 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2018 | 441 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2018 | 3053 | 0.030 |
Why?
| Organ Size | 1 | 2017 | 435 | 0.030 |
Why?
| Congenital Abnormalities | 1 | 2017 | 73 | 0.030 |
Why?
| Graft Rejection | 1 | 2019 | 516 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 731 | 0.030 |
Why?
| Pregnancy | 2 | 2018 | 5527 | 0.030 |
Why?
| Up-Regulation | 1 | 2019 | 812 | 0.030 |
Why?
| Biopsy | 1 | 2019 | 1045 | 0.030 |
Why?
| Survival Analysis | 1 | 2019 | 1220 | 0.030 |
Why?
| Waiting Lists | 1 | 2017 | 211 | 0.030 |
Why?
| Cerebrovascular Circulation | 1 | 2018 | 220 | 0.030 |
Why?
| Interleukin-6 | 1 | 2019 | 676 | 0.030 |
Why?
| Neuroimaging | 1 | 2018 | 248 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2018 | 817 | 0.030 |
Why?
| Immunoglobulin G | 1 | 2019 | 776 | 0.030 |
Why?
| Protein Binding | 1 | 2019 | 1897 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1801 | 0.030 |
Why?
| Autoimmunity | 1 | 2019 | 818 | 0.030 |
Why?
| Survival Rate | 1 | 2018 | 1644 | 0.030 |
Why?
| Intestinal Mucosa | 1 | 2018 | 530 | 0.030 |
Why?
| Neuropsychological Tests | 1 | 2018 | 913 | 0.030 |
Why?
| Premature Birth | 1 | 2017 | 276 | 0.030 |
Why?
| Overweight | 1 | 2017 | 472 | 0.030 |
Why?
| Glucose | 1 | 2018 | 897 | 0.030 |
Why?
| Recovery of Function | 1 | 2017 | 572 | 0.030 |
Why?
| Mice, Knockout | 1 | 2019 | 2586 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2019 | 1270 | 0.030 |
Why?
| Age Factors | 1 | 2020 | 2891 | 0.030 |
Why?
| Genotype | 1 | 2018 | 1775 | 0.030 |
Why?
| Retrospective Studies | 2 | 2020 | 12544 | 0.030 |
Why?
| Proteomics | 1 | 2018 | 844 | 0.030 |
Why?
| Mothers | 1 | 2018 | 651 | 0.030 |
Why?
| Autoantibodies | 1 | 2019 | 1354 | 0.020 |
Why?
| Cytokines | 1 | 2019 | 1843 | 0.020 |
Why?
| Rats | 1 | 2018 | 4963 | 0.020 |
Why?
| Hyperlipidemias | 1 | 2011 | 122 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3549 | 0.020 |
Why?
| Income | 1 | 2011 | 167 | 0.020 |
Why?
| Mental Recall | 1 | 2011 | 170 | 0.020 |
Why?
| Blood Glucose | 1 | 2018 | 1821 | 0.020 |
Why?
| Social Class | 1 | 2011 | 204 | 0.020 |
Why?
| Educational Status | 1 | 2011 | 409 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2011 | 362 | 0.020 |
Why?
| Learning | 1 | 2011 | 352 | 0.020 |
Why?
| Infant | 1 | 2018 | 7937 | 0.020 |
Why?
| Smoking | 1 | 2011 | 1391 | 0.010 |
Why?
| Diabetes Mellitus | 1 | 2011 | 904 | 0.010 |
Why?
| Depression | 1 | 2011 | 1134 | 0.010 |
Why?
| Stroke | 1 | 2011 | 1019 | 0.010 |
Why?
|
|
You's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|